Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603)

被引：0

作者：

Jahn, Nikolaus ^{[1
]}

Panina, Ekaterina ^{[1
]}

Bullinger, Lars ^{[2
]}

Dolnik, Anna ^{[2
]}

Herzig, Julia ^{[1
]}

Blaette, Tamara J. ^{[2
]}

Benner, Axel ^{[3
]}

Krzykalla, Julia ^{[3
]}

Gathmann, Insa ^{[4
]}

Larson, Richard A. ^{[5
,6
]}

Lo-Coco, Francesco ^{[7
]}

Amadori, Sergio ^{[7
]}

Prior, Thomas W. ^{[8
]}

Brandwein, Joseph M. ^{[9
]}

Appelbaum, Frederick R. ^{[10
]}

Medeiros, Bruno C. ^{[11
]}

Tallman, Martin S. ^{[12
]}

Tiecke, Eva ^{[13
]}

Pallaud, Celine ^{[14
]}

Ehninger, Gerhard ^{[15
]}

Heuser, Michael ^{[16
]}

Ganser, Arnold ^{[16
]}

Stone, Richard M. ^{[17
]}

Thiede, Christian ^{[15
]}

Doehner, Hartmut ^{[1
]}

Bloomfield, Clara D. ^{[8
]}

Doehner, Konstanze ^{[1
]}

机构：

[1] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany

[2] Charite, Dept Hematol Oncol & Tumorimmunol, Berlin, Germany

[3] German Canc Res Ctr, Div Biostat, Heidelberg, Germany

[4] Novartis Pharma AG, Basel, Switzerland

[5] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA

[6] Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA

[7] Univ Roma Tor Vergata, Rome, Italy

[8] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[9] Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON, Canada

[10] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA

[11] Stanford Univ, Ctr Canc, Stanford, CA 94305 USA

[12] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA

[13] Novartis Pharmaceut, Basel, Switzerland

[14] Novartis Pharmaceut, Oncol Precis Med, Novartis Oncol BU, Basel, Switzerland

[15] Univ Hosp Carl Gustav Carus, Internal Med 1, Dresden, Germany

[16] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany

[17] Dana Farber Partners CancerCare, Dept Med Oncol, Boston, MA USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-115842

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1534

引用

页数：6

共 50 条

[41] Follow-up of Patients With FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukaemia in the Phase 3 ADMIRAL Trial [J].

Perl, Alexander E. ;

Larson, Richard A. ;

Podoltsev, Nikolai A. ;

Strickland, Stephen ;

Wang, Eunice S. ;

Atallah, Ehab ;

Schiller, Gary J. ;

Martinelli, Giovanni ;

Neubauer, Andreas ;

Sierra, Jorge ;

Montesinos, Pau ;

Recher, Christian ;

Yoon, Sung-Soo ;

Hosono, Naoko ;

Onozawa, Masahiro ;

Chiba, Shigeru ;

Kim, Hee-Je ;

Hasabou, Nahla ;

Lu, Qiaoyang ;

Tiu, Ramon ;

Levis, Mark J. .

BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 :6-7

[42] Outcomes with Sequential FLT3-Inhibitor (FLT3i) Based Therapies in Patients (pts) with FLT3-Mutated Acute Myeloid Leukemia (AML) Exposed to Prior FLT3i Based Therapies [J].

Yilmaz, Musa ;

Alfayez, Mansour ;

Kadia, Tapan M. ;

DiNardo, Courtney D. ;

Borthakur, Gautam ;

Loghavi, Sanam ;

Konopleva, Marina ;

Kanagal-Shamanna, Rashmi ;

Patel, Keyur ;

Jabbour, Elias ;

Garcia-Manero, Guillermo ;

Pemmaraju, Naveen ;

Pierce, Sherry A. ;

Issa, Ghayas C. ;

Short, Nicholas J. ;

Bravo, Guillermo Montalban ;

Takahashi, Koichi ;

Assi, Rita ;

Alotaibi, Ahmad S. ;

Andreeff, Michael ;

Cortes, Jorge E. ;

Kantarjian, Hagop M. ;

Ravandi, Farhad ;

Daver, Naval .

BLOOD, 2020, 136

[43] Venetoclax Plus Hypomethylating Agent (HMA) Based Induction for Treatment-Naive Older/Unfit Patients with FLT3-Mutated Acute Myeloid Leukemia (AML) [J].

Ghorab, Ahmad ;

Litzow, Mark R. ;

Gangat, Naseema ;

Al-Kali, Aref ;

Shah, Mithun, V ;

Murthy, Hemant S. ;

Tefferi, Ayalew ;

Alkhateeb, Hassan B. ;

Begna, Kebede ;

Patnaik, Mrinal M. ;

Foran, James M. ;

Badar, Talha .

BLOOD, 2022, 140 :9019-9020

[44] Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: results from the phase 3 ADMIRAL trial [J].

Perl, A. E. ;

Martinelli, G. ;

Cortes, J. E. ;

Neubauer, A. ;

Berman, E. ;

Paolini, S. ;

Montesinos, P. ;

Baer, M. R. ;

Larson, R. A. ;

Ustun, C. ;

Fabbiano, F. ;

Di Stasi, A. ;

Stuart, R. ;

Olin, R. ;

Kasner, M. ;

Ciceri, F. ;

Chou, W. -C. ;

Podoltsev, N. ;

Recher, C. ;

Yokoyama, H. ;

Hosono, N. ;

Yoon, S. -S. ;

Lee, J. -H. ;

Pardee, T. ;

Fathi, A. T. ;

Liu, C. ;

Liu, X. ;

Bahceci, E. ;

Levis, M. J. .

ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 :295-295

[45] Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial [J].

Smith, Catherine C. ;

Levis, Mark J. ;

Perl, Alexander E. ;

Martinelli, Giovanni ;

Neubauer, Andreas ;

Berman, Ellin ;

Montesinos, Pau ;

Baer, Maria R. ;

Larson, Richard A. ;

Chou, Wen-Chien ;

Yokoyama, Hisayuki ;

Recher, Christian ;

Yoon, Sung-Soo ;

Hill, Jason E. ;

Rosales, Matt ;

Bahceci, Erkut .

BLOOD, 2019, 134

[46] CLONAL EVOLUTION OF FLT3-ITD POSITIVE AML AT DIAGNOSIS AND RELAPSE IN PATIENTS TREATED WITHIN THE CALGB 10603 (RATIFY) AND AMLSG 16-10 TRIALS [J].

Schmalbrock, L. K. ;

Cocciardi, S. ;

Dolnik, A. ;

Agrawal, M. ;

Theis, F. ;

Jahn, N. ;

Blaette, T. J. ;

Gaidzik, V. I. ;

Paschka, P. ;

Fiedler, W. ;

Salih, H. ;

Wulf, G. ;

Germing, U. ;

Luebbert, M. ;

Thol, F. ;

Heuser, M. ;

Larson, R. A. ;

Ganser, A. ;

Schlenk, R. F. ;

Stone, R. M. ;

Doehner, H. ;

Doehner, K. ;

Bullinger, L. .

HAEMATOLOGICA, 2017, 102 :358-358

[47] Treatment With FLT3 Inhibitor in Patients With FLT3-Mutated Acute Myeloid Leukemia Is Associated With Development of Secondary FLT3-Tyrosine Kinase Domain Mutations [J].

Alvarado, Yesid ;

Kantarjian, Hagop M. ;

Luthra, Rajyalakshmi ;

Ravandi, Farhad ;

Borthakur, Gautam ;

Garcia-Manero, Guillermo ;

Konopleva, Marina ;

Estrov, Zeev ;

Andreeff, Michael ;

Cortes, Jorge E. .

CANCER, 2014, 120 (14) :2142-2149

[48] GILTERITINIB SIGNIFICANTLY PROLONGS OVERALL SURVIVAL IN PATIENTS WITH FLT3-MUTATED RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA: RESULTS FROM THE PHASE 3 ADMIRAL TRIAL [J].

Perl, A. E. ;

Martinelli, G. ;

Cortes, J. E. ;

Neubauer, A. ;

Berman, E. ;

Paolini, S. ;

Montesinos, P. ;

Baer, M. R. ;

Larson, R. A. ;

Ustun, C. ;

Fabbiano, F. ;

Di Stasi, A. ;

Stuart, R. ;

Olin, R. ;

Kasner, M. ;

Ciceri, F. ;

Chou, W. ;

Podoltsev, N. ;

Recher, C. ;

Yokoyama, H. ;

Hosono, N. ;

Yoon, S. ;

Pardee, J. Lee T. ;

Fathi, A. T. ;

Liu, C. ;

Liu, X. ;

Bahceci, E. ;

Levis, M. J. .

HAEMATOLOGICA, 2019, 104 :2-2

[49] Azacitidine and Venetoclax Followed By Sequential Gilteritinib Is an Effective Alternative in Very Frail Patients with FLT3-Mutated Acute Myeloid Leukemia [J].

Nedumannil, Rithin ;

Matley, Chelsea ;

Bajel, Ashish ;

Levis, Mark J. ;

Wei, Andrew H. .

BLOOD, 2024, 144 :6060-6061

[50] Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study [J].

Menna, Pierantonio ;

Marchesi, Francesco ;

Cattaneo, Chiara ;

Candoni, Anna ;

Delia, Mario ;

Nadali, Gianpaolo ;

Vatteroni, Alessandra ;

Pasciolla, Crescenza ;

Perrone, Salvatore ;

Verga, Luisa ;

Armiento, Daniele ;

Del Principe, Maria Ilaria ;

Fracchiolla, Nicola S. S. ;

Salvatorelli, Emanuela ;

Lupisella, Santina ;

Terrenato, Irene ;

Busca, Alessandro ;

Minotti, Giorgio ;

Pagano, Livio .

CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (10) :1876-1885

← 1 2 3 4 5 →